JP2021521437A5 - - Google Patents

Info

Publication number
JP2021521437A5
JP2021521437A5 JP2020555818A JP2020555818A JP2021521437A5 JP 2021521437 A5 JP2021521437 A5 JP 2021521437A5 JP 2020555818 A JP2020555818 A JP 2020555818A JP 2020555818 A JP2020555818 A JP 2020555818A JP 2021521437 A5 JP2021521437 A5 JP 2021521437A5
Authority
JP
Japan
Prior art keywords
cancer
wnt
catenin signaling
signaling modulator
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020555818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521437A (ja
JP7292306B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/050334 external-priority patent/WO2019195897A1/en
Publication of JP2021521437A publication Critical patent/JP2021521437A/ja
Publication of JP2021521437A5 publication Critical patent/JP2021521437A5/ja
Application granted granted Critical
Publication of JP7292306B2 publication Critical patent/JP7292306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020555818A 2018-04-13 2019-04-12 処置に対する応答をモニターする方法 Active JP7292306B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901242 2018-04-13
AU2018901242A AU2018901242A0 (en) 2018-04-13 Method of monitoring response to a treatment
PCT/AU2019/050334 WO2019195897A1 (en) 2018-04-13 2019-04-12 Method of monitoring response to a treatment

Publications (3)

Publication Number Publication Date
JP2021521437A JP2021521437A (ja) 2021-08-26
JP2021521437A5 true JP2021521437A5 (cg-RX-API-DMAC10.html) 2022-04-08
JP7292306B2 JP7292306B2 (ja) 2023-06-16

Family

ID=68163410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555818A Active JP7292306B2 (ja) 2018-04-13 2019-04-12 処置に対する応答をモニターする方法

Country Status (5)

Country Link
US (1) US20210148894A1 (cg-RX-API-DMAC10.html)
JP (1) JP7292306B2 (cg-RX-API-DMAC10.html)
CN (1) CN111971559A (cg-RX-API-DMAC10.html)
AU (1) AU2019251518A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019195897A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944649C (en) * 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171771B1 (en) 1999-04-09 2005-06-29 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker
CN101166979A (zh) * 2005-05-11 2008-04-23 霍夫曼-拉罗奇有限公司 化学治疗应答者的确定
US20080305962A1 (en) * 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
WO2012129517A2 (en) * 2011-03-24 2012-09-27 Dyax Corp. Evaluating protein expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
TWI504390B (zh) * 2012-09-18 2015-10-21 Univ China Medical 苯醌類化合物應用於抑制黑色素瘤細胞之Ｗｎｔ／β－ｃａｔｅｎｉｎ訊息途徑之用途
RU2702908C2 (ru) * 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы

Similar Documents

Publication Publication Date Title
Lodato et al. Adverse effects of proton pump inhibitors
Aapro et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer
US20200405727A1 (en) New alk inhibitor senolytic drugs
Sashidhara et al. Identification of quinoline-chalcone hybrids as potential antiulcer agents
Patel et al. Smad3-dependent and-independent pathways are involved in peritoneal membrane injury
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
Goncalves et al. Violacein induces death of RAS-mutated metastatic melanoma by impairing autophagy process
Singh et al. Genetic and epigenetic alterations in Toll like receptor 2 and wound healing impairment in type 2 diabetes patients
Marzinke et al. Decreased Escitalopram Concentrations Post–Roux-en-Y Gastric Bypass Surgery
RU2603462C2 (ru) Лечение фармакологически индуцированной гипохлоргидрии
CN107427502A (zh) 使用川地匹坦的治疗方法
Yang et al. The Apelin/APLNR system modulates tumor immune response by reshaping the tumor microenvironment
JP2017096785A (ja) 組織線維化スクリーニング方法および抗組織線維化薬剤ならびに機能性食品
JP2024520898A5 (cg-RX-API-DMAC10.html)
Li et al. Inhibition of Nuclear Factor Kappa B as a Therapeutic Target for Lung Cancer.
Bazargan et al. Successful treatment of resistant plantar ulcerative lichen planus with tofacitinib: a case report and comprehensive review of the literature
Lalau et al. Metformin accumulation without hyperlactataemia and metformin-induced hyperlactataemia without metformin accumulation
Gahr et al. Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma-review of the underlying molecular mechanisms and first case report
Hunt et al. The pharmacodynamics and pharmacokinetics of S‐tenatoprazole‐Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects
Mourad et al. Mechanisms of antiangiogenic-induced arterial hypertension
AU2025200383A1 (en) Animal, Fungal and Marine Sources of cGP and Increased cGP Concentration for Disease Management and for Treatment of Non-Neurological and/or Neurological Conditions
Kuo et al. Dithiolethione ACDT suppresses neuroinflammation and ameliorates disease severity in experimental autoimmune encephalomyelitis
Zeng et al. Acupuncture improves depression-like behaviors in rats through gut microbiota and TLR4/MyD88/NF-κB pathway modulation
Vardy et al. Emerging therapeutics for Alzheimer’s disease
Han et al. Indole-3-acetic acid exerts protective effects on sleep deprivation-induced cognitive impairment